Background: Ex vivo lung perfusion (EVLP) provides opportunities to treat injured donor lungs before transplantation. We investigated whether lung lavage, to eliminate inflammatory inhibitory components, followed by exogenous surfactant replacement, could aid lung recovery and improve post-transplant lung function after gastric aspiration injury.

Methods: Gastric acid aspiration was induced in donor pigs, which were ventilated for 6 hours to develop lung injury. After retrieval and 10 hours of cold preservation, EVLP was performed for 6 hours. The lungs were randomly divided into 4 groups (n = 5, each): (1) no treatment (control), (2) lung lavage, (3) surfactant administration, and (4) lung lavage, followed by surfactant administration. After another 2-hour period of cold preservation, the left lung was transplanted and reperfused for 4 hours.

Results: Physiologic lung function significantly improved after surfactant administration during EVLP. The EVLP perfusate from the lavage + surfactant group showed significantly lower levels of interleukin (IL)-1β, IL-6, IL-8, and secretory phospholipase A. Total phosphatidylcholine was increased, and minimum surface tension was recovered to normal levels (≤5 mN/m) in the bronchioalveolar fluid after surfactant administration. Lysophosphatidylcholine in bronchioalveolar fluid was significantly lower in the lavage + surfactant group than in the surfactant group. Post-transplant lung function was significantly better in the lavage + surfactant group compared with all other groups.

Conclusions: Lung lavage, followed by surfactant replacement during EVLP, reduced inflammatory mediators and prevented hydrolysis of phosphatidylcholine, which contributed to the superior post-transplant function in donor lungs with aspiration injury.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healun.2016.11.010DOI Listing

Publication Analysis

Top Keywords

lavage surfactant
28
lung lavage
20
surfactant administration
16
surfactant group
16
lung
14
surfactant replacement
12
lung function
12
surfactant
11
vivo lung
8
lung perfusion
8

Similar Publications

Inhaled ozone induces distinct alterations in pulmonary function in models of acute and episodic exposure in female mice.

Toxicol Sci

January 2025

Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, 08854.

Ozone is an urban air pollutant, known to cause lung injury and altered function. Using established models of acute (0.8 ppm, 3 h) and episodic (1.

View Article and Find Full Text PDF

Pulmonary surfactant is a membranous complex that enables breathing dynamics at the respiratory surface. Extremely low values of surface tension are achieved at end-expiration thanks to a unique mixture of lipids and proteins. In particular, the hydrophobic surfactant proteins, specially the protein SP-B, are crucial for surfactant biophysical function, in order to provide the surfactant lipid matrix with the ability to form membranous multi-layered interfacial films that sustain optimal mechanical properties.

View Article and Find Full Text PDF

Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli.

View Article and Find Full Text PDF

Anesthesia Management of the Patient With Pulmonary Alveolar Proteinosis Undergoing Lung Lavage.

AANA J

December 2024

Clinical Assistant Professor, Department of Nurse Anesthesia Education, University of Kansas Medical Center, Kansas City, Kansas.

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder characterized by the accumulation of surfactant/lipoprotein material in the alveoli and subsequent hypoxemic respiratory failure. Whole lung lavage (WLL), a procedure used to physically remove the lipoprotein material from the alveoli, is the first-line treatment for this disease process. Anesthesia providers may infrequently encounter the management of the WLL procedure due to the rarity of the underlying disease process.

View Article and Find Full Text PDF
Article Synopsis
  • Pulmonary alveolar proteinosis (PAP) is a lung disease involving the buildup of lipoprotein material in alveoli due to surfactant issues, with whole lung lavage (WLL) being the main treatment since the 1960s.
  • Autoimmune PAP, the most common type, results from antibodies affecting a crucial growth factor; however, there are currently no international treatment guidelines, and therapeutic strategies depend on PAP type and severity.
  • Although WLL techniques have progressed, a standardized protocol is lacking, making careful planning and patient evaluation critical for successful treatment outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!